This week, the newly private Tripos launched its first software package following its acquisition by Vector Capital in mid-March, while its publicly traded counterpart faces delisting from the Nasdaq Stock Market, which deemed the firm a “public shell” on Wednesday.
 
The existence of two entities operating under the same name has led to some confusion in the marketplace, according to Jim Hopkins, CEO of the privately held discovery informatics, which has taken to calling itself the “New Tripos.”  
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.